vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
vTv Therapeutics announced the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study testing oral cadisegliatin in adults with type 1 diabetes who use hybrid closed-loop insulin delivery systems. The ~40-person, six-week crossover study is designed to complement the already fully enrolled Phase 3 CATT1 trial, which only covered open-loop insulin users, and to inform design of future Phase 3 research in the AID segment.
Key figures
- Drug Name
- cadisegliatin (TTP399)
- Phase Of Trial
- Phase 2a
- Study design
- double-blind, randomized, placebo-controlled, two-way crossover
- Primary endpoint
- CGM-based measures of glycemic control including Time in Range (TIR)
- Aid adoption rate
- up to 40% of people with T1D
- Us t1d population
- 2.1 million
- Treatment duration
- six weeks of treatment
- Expected enrollment
- approximately 40 adults
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.